Prof. Groop (Helsinki, Finland)

Linagliptin really helps simplify the management of T2D. So the efficacy of linagliptin is proven as monotherapy, or also in combination, and has been demonstrated in patients with very high baseline A_1c . Linagliptin is the only DPP4 inhibitor with an established CV and kidney safety profile with multiple sub-analyses demonstrated in a robust and unique development programme including two unique CVOTs. Why do I say unique? Yes, because CARMELINA® was not only a CVOT. When it was designed, they also included patients with kidney disease so we could get information also on kidney safety. And CAROLINA® was unique in the sense that it had an active comparator. So, two unique trials provided a lot of important evidence and helps us when we tailor the treatment for our patients. And finally, linagliptin offers a simple way to manage patients with T2D. Always one dose, once daily for a broad range of patients, and that is actually the theme of today: simplicity. Linagliptin provides that simplicity when we tailor the treatment for our patients.